Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dbv Technologies ADR (NQ: DBVT )

0.7612 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dbv Technologies ADR

< Previous 1 2 3 4 5 6 7 8 Next >
DBV Technologies Advances Peanut Allergy Program With FDA Support On Pediatric Studies
DBV Technologies (NASDAQ: DBVT) received Type C meeting written responses from the FDA on key study design elements for the COMFORT Toddlers and COMFORT Children supplemental safety studies in 1 –... 
Via Benzinga
DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update
From DBV Technologies S.A.
Via GlobeNewswire
Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023
From DBV Technologies S.A.
Via GlobeNewswire
Earnings Preview: DBV Technologies
Via Benzinga
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
From DBV Technologies S.A.
Via GlobeNewswire
Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2023
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in Upcoming EAACI Congress 2023
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in Upcoming Investor Conference
From DBV Technologies S.A.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 
Via Benzinga
Why Shares of DBV Technologies Jumped Thursday
The New England Journal of Medicine reported phase 3 trial details regarding the company's peanut allergy treatment for toddlers. 
Via The Motley Fool
Good News For Toddlers With Peanut Allergy: DBVT Data Shows Promising Results for Peanut Allergy Patch
DBV Technologies (NASDAQ: DBVT) (OTC:  
Via Benzinga
DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in Upcoming Investor Conference
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Reports First Quarter 2023 Financial Results
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Outlines Regulatory Path For Viaskin Peanut Allergy Patch For Kids Below 3 Years
DBV Technologies (NASDAQ: DBVT) received written responses from the FDA on the regulatory path for the investigational Viaskin Peanut 250 μg patch (DBV712) in toddlers ages 1 – 3 years old with a... 
Via Benzinga
DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting
From DBV Technologies S.A.
Via GlobeNewswire
7 Penny Stocks Sitting in the Sweet Spot
If you can handle the ever-present threat of extreme volatility, these analyst-supported penny stocks could be interesting. 
Via InvestorPlace
Ordinary and Extraordinary General Meeting of April 12, 2023
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Update
From DBV Technologies S.A.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies Reports Full Year 2022 Financial Results and Business Update
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in Upcoming AAAAI 2023 Congress
From DBV Technologies S.A.
Via GlobeNewswire
DBV Technologies to Participate in Upcoming Investor Conference
From DBV Technologies S.A.
Via GlobeNewswire
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
From DBV Technologies S.A.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.